VolitionRx Limited Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
VolitionRx Limited (VNRX) reported Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax of $146.30 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-03-31
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-12-31 was $260.60K, a 49.54% decline year-over-year.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-09-30 was -$31.43K.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-06-30 was $29.99K, a 59.81% decline year-over-year.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-03-31 was -$112.85K.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2025 was $146.30K, a 49.58% decline from fiscal 2024.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2024 was $290.15K.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2022 was $329.68K, a 88.26% increase from fiscal 2021.
- VolitionRx Limited income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2021 was $175.12K, a 271.17% increase from fiscal 2020.
| Period end | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 3 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 6 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 9 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $260.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $229.16K derived: sum of 2 quarters · filed 2026-03-31 | $259.15K derived: sum of 3 quarters · filed 2026-03-31 | $146.30K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$31.43K 10-Q · filed 2025-11-13 | -$1.44K derived: sum of 2 quarters · filed 2025-11-13 | -$114.29K 10-Q · filed 2025-11-13 | $402.15K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | $29.99K 10-Q · filed 2025-08-14 | $82.86K 10-Q · filed 2025-08-14 | $433.58K derived: sum of 3 quarters · filed 2026-03-31 | $386.54K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | -$112.85K derived: 10-K 12 month − 3 quarters · filed 2026-03-31 | $403.59K derived: sum of 2 quarters · filed 2026-03-31 | $356.54K derived: sum of 3 quarters · filed 2026-03-31 | $431.17K derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | $516.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $469.39K derived: sum of 2 quarters · filed 2026-03-31 | $544.02K derived: sum of 3 quarters · filed 2026-03-31 | $290.15K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$47.05K 10-Q · filed 2025-11-13 | $27.58K derived: sum of 2 quarters · filed 2025-11-13 | -$226.29K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $74.63K 10-Q · filed 2025-08-14 | $179.25K 10-Q · filed 2025-08-14 | ||
| 2022-12-31 | $94.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $163.40K derived: sum of 2 quarters · filed 2023-03-15 | $245.70K derived: sum of 3 quarters · filed 2023-03-15 | $329.68K 10-K · filed 2023-03-15 |
| 2022-09-30 | $69.31K 10-Q · filed 2022-11-14 | $151.61K derived: sum of 2 quarters · filed 2022-11-14 | $235.58K 10-Q · filed 2022-11-14 | $308.67K derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | $82.30K 10-Q · filed 2022-08-10 | $166.28K 10-Q · filed 2022-08-10 | $239.37K derived: sum of 3 quarters · filed 2023-03-15 | $284.43K derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | $83.98K 10-Q · filed 2022-05-11 | $157.06K derived: sum of 2 quarters · filed 2023-03-15 | $202.13K derived: sum of 3 quarters · filed 2023-03-15 | $249.67K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | $73.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $118.15K derived: sum of 2 quarters · filed 2023-03-15 | $165.69K derived: sum of 3 quarters · filed 2023-03-15 | $175.12K 10-K · filed 2023-03-15 |
| 2021-09-30 | $45.06K 10-Q · filed 2022-11-14 | $92.60K derived: sum of 2 quarters · filed 2022-11-14 | $102.03K 10-Q · filed 2022-11-14 | $125.81K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $47.54K 10-Q · filed 2022-08-10 | $56.96K 10-Q · filed 2022-08-10 | $80.75K derived: sum of 3 quarters · filed 2022-08-10 | $88.80K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $9.42K 10-Q · filed 2022-05-11 | $33.21K derived: sum of 2 quarters · filed 2022-05-11 | $41.26K derived: sum of 3 quarters · filed 2022-05-11 | $47.04K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $23.78K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $31.83K derived: sum of 2 quarters · filed 2022-03-30 | $37.61K derived: sum of 3 quarters · filed 2022-03-30 | $47.18K 10-K · filed 2022-03-30 |
| 2020-09-30 | $8.05K 10-Q · filed 2021-11-10 | $13.83K derived: sum of 2 quarters · filed 2021-11-10 | $23.40K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.78K 10-Q · filed 2021-08-11 | $15.35K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $9.57K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |